Cyclacel Pharmaceuticals Inc. (CYCC)
$5.13
$-1.64
(-24.22%)
As on 10-Oct-2025 09:30EDT
Market cap
$14 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0
P/B Ratio
3.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-90.7
-
Face value
--
-
Shares outstanding
2,238,980
10 Years Aggregate
CFO
$-130.28 Mln
EBITDA
$-174.03 Mln
Net Profit
$-139.19 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cyclacel Pharmaceuticals (CYCC)
| -94.3 | -23.0 | 37.5 | -97.3 | -89.6 | -79.5 | -68.0 |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Cyclacel Pharmaceuticals (CYCC)
| -85.7 | -73.3 | -82.8 | -50.2 | -41.7 | 10.7 | -65.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or... plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Read more
-
President, CEO & Executive Director
Mr. Spiro George Rombotis
-
President, CEO & Executive Director
Mr. Spiro George Rombotis
-
Headquarters
Kuala Lumpur
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cyclacel Pharmaceuticals (CYCC)
What is the current share price of Cyclacel Pharmaceuticals Inc (CYCC) Today?
The share price of Cyclacel Pharmaceuticals Inc (CYCC) is $5.13 (NASDAQ) as of 10-Oct-2025 09:30 EDT. Cyclacel Pharmaceuticals Inc (CYCC) has given a return of -89.64% in the last 3 years.
What is the current PB & PE ratio of Cyclacel Pharmaceuticals Inc (CYCC)?
Since, TTM earnings of Cyclacel Pharmaceuticals Inc (CYCC) is negative, P/E ratio is not available.
The P/B ratio of Cyclacel Pharmaceuticals Inc (CYCC) is 3.68 times as on 10-Oct-2025, a 29 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
0.00 |
-0.01 |
2023 |
-0.10 |
3.76 |
2022 |
-0.03 |
0.03 |
2021 |
-0.14 |
0.07 |
2020 |
-0.62 |
0.16 |
What is the 52 Week High and Low of Cyclacel Pharmaceuticals Inc (CYCC)?
The 52-week high and low of Cyclacel Pharmaceuticals Inc (CYCC) are Rs 597.60 and Rs 3.08 as of 01-Sep-2026.
What is the market cap of Cyclacel Pharmaceuticals Inc (CYCC)?
Cyclacel Pharmaceuticals Inc (CYCC) has a market capitalisation of $ 14 Mln as on 10-Oct-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Cyclacel Pharmaceuticals Inc (CYCC)?
Before investing in Cyclacel Pharmaceuticals Inc (CYCC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.